Merck stock trades steady as Keytruda growth supports earnings outlook

Merck & Co., Inc. (ISIN US58933Y1055) remains a core healthcare name in the US equity market, with Merck stock on the New York Stock Exchange reflecting a business increasingly driven by oncology and vaccines. In full-year 2023, Merck reported worldwide sales of roughly $60.1 billion, up from around $59.3 billion in 2022, signaling modest top-line growth after the loss of Covid-19 treatment revenue. The company’s valuation continues to be anchored by blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil, which together represent a large share of Merck’s pharmaceutical revenue.

Keytruda revenue up double digits

Oncology therapies are the centerpiece of Merck’s growth strategy, and Keytruda is the leading contributor. In full-year 2023, Keytruda global sales were reported at approximately $25.0 billion, an increase of about 19% compared with roughly $21.0 billion in 2022, highlighting sustained demand across multiple indications and geographies. This growth rate is notable given the drug’s already very high revenue base and reflects new approvals in earlier-stage cancers as well as expanded use in lung cancer and other solid tumors. The strong Keytruda performance provides Merck with a recurring cash flow stream that supports research spending and potential business development, even as the company prepares for eventual loss of exclusivity.

Outside oncology, vaccines remain a critical pillar. Merck’s HPV vaccine franchise, sold under the Gardasil and Gardasil 9 brands, generated around $8.0 billion in sales in 2023, up from roughly $6.9 billion in 2022, corresponding to year-on-year growth of about 16%. This increase was driven by higher demand in the United States and selected international markets, including expanded immunization programs and catch-up vaccination in adolescents and young adults. For investors, the combined revenue from Keytruda and Gardasil in 2023 therefore represents more than half of Merck’s total sales, underscoring the company’s reliance on a limited number of high-performing products.

2023 earnings and margin profile

Merck’s earnings profile has been reshaped by the sharp decline in Covid-19 treatment sales. The antiviral Lagevrio (molnupiravir), which had delivered several billion dollars of revenue in 2022, contributed significantly less in 2023 as pandemic-related demand receded, resulting in a slight slowdown in total company sales growth despite the strong performance of oncology and vaccines. According to Merck’s 2023 annual figures, non-GAAP earnings per share (EPS) were reported at approximately $2.98, compared with about $7.48 in 2022, reflecting the normalization of Covid-related earnings, higher research and development expenses, and acquisition-related costs. The decline in EPS is thus driven more by temporary Covid dynamics and investment than by weakness in the core portfolio.

From a profitability standpoint, Merck’s non-GAAP gross margin in 2023 remained robust, supported by the high-margin nature of specialty medicines like Keytruda. Research and development (R&D) expenses were roughly $13.5 billion in 2023, up from about $13.0 billion in 2022, illustrating Merck’s continued commitment to pipeline expansion in oncology, vaccines, and cardiometabolic diseases. Selling, general, and administrative (SG&A) costs also rose moderately, consistent with broader inflationary pressures and commercial investments. This cost trajectory suggests that Merck is prioritizing long-term innovation over near-term margin optimization, a typical pattern for large-cap pharmaceutical companies with blockbuster franchises.

Dividend and cash flow support

Income-oriented investors often view Merck stock as a defensive holding because of its dividend track record. In 2023, Merck paid an annual dividend of roughly $2.92 per share, up from about $2.76 per share in 2022, implying a year-on-year increase of around 6%. The company’s dividend yield, based on typical trading levels over the period, has generally ranged in the mid-single-digit percentage area, depending on the share price. This payout is supported by Merck’s substantial operating cash flow; in 2023, operating cash flow was in the tens of billions of dollars, underpinned by recurring revenue from Keytruda and vaccines. The dividend policy is therefore an important element of Merck’s equity story, providing a regular return component alongside potential capital appreciation.

Merck also deploys capital through occasional share repurchases, although the company’s primary uses of cash remain research investments, acquisitions, and the dividend. The balance sheet profile is relatively conservative compared with some industrial sectors, with manageable net debt levels supported by strong and recurring cash generation. For long-term holders, the combination of a growing dividend, robust cash flows, and a diversified pipeline helps mitigate the risk associated with individual product patent cliffs.

Pipeline and patent considerations

Looking beyond current revenue drivers, Merck’s pipeline includes a range of oncology assets, vaccines, and cardiometabolic candidates intended to complement or eventually offset Keytruda as it approaches expected patent expiries in the late 2020s. The company is developing next-generation cancer immunotherapies and combination regimens designed to maintain leadership in immune-oncology. In vaccines, Merck continues to invest in formulations targeting diseases such as pneumococcal infections and other viral pathogens, leveraging its experience with Gardasil.

Patent protection for Keytruda is a central strategic topic. As Keytruda accounts for around 40% of Merck’s total 2023 revenue, the eventual loss of exclusivity poses a material long-term challenge. Merck is therefore pursuing both internal pipeline progress and external dealmaking to diversify its revenue base. This includes collaborations and acquisitions in areas like cardiovascular disease and immunology, where potential new large-scale medicines could help cushion the impact once biosimilar competition emerges for Keytruda. For Merck stock, investors often weigh current earnings strength against these future patent dynamics when assessing valuation multiples.

Gardasil growth underpins vaccine strategy

Gardasil’s strong double-digit revenue growth in 2023 illustrates the resilience of Merck’s vaccine portfolio. With approximately $8.0 billion in sales, Gardasil accounted for around 13% of total company revenue, and its growth rate of roughly 16% year-on-year reflects increased vaccination rates and broader geographical reach. The HPV vaccine addresses a significant public health need, helping to prevent cervical and other HPV-related cancers. Public health initiatives and reimbursement frameworks in major markets have played a crucial role in expanding uptake.

The vaccine segment also benefits from long-term contracts and government procurement programs, which can lend visibility to future revenue streams. However, vaccines typically face competition from other manufacturers and from evolving guidelines, so Merck continues to invest in both clinical data and manufacturing capacity to support Gardasil’s position. For investors following Merck stock, Gardasil provides a second growth engine alongside Keytruda, with different regulatory and competitive dynamics that can partly balance oncology-specific risks.

Shares valued on large-cap pharma metrics

Merck is a large-cap pharmaceutical company listed on the New York Stock Exchange, and Merck stock is typically valued on earnings multiples that reflect both growth prospects and the defensive quality associated with healthcare demand. Market capitalization has generally been in the range of tens of billions of dollars, supported by the company’s status as a major constituent in broad US indices such as the S&P 500. At common valuation points over recent periods, Merck’s price-to-earnings ratio has reflected the market’s expectation of continued double-digit growth in Keytruda and Gardasil, balanced against future patent and competitive pressures.

Merck’s share price often responds to clinical trial readouts and regulatory decisions, particularly for oncology and vaccine assets. Positive late-stage data or new approvals can reinforce the growth narrative and influence analyst estimates for future revenue and earnings. Conversely, setbacks in the pipeline or adverse regulatory outcomes can weigh on sentiment. As a result, Merck stock tends to trade not only on current financial metrics but also on evolving expectations regarding its scientific portfolio, making clinical news a key driver of medium-term performance.

Keytruda indications expand

Keytruda’s revenue growth in 2023 was underpinned by its expanding label across a broad spectrum of cancers, including non-small cell lung cancer, melanoma, renal cell carcinoma, and others. The drug operates as a programmed death receptor-1 (PD-1) blocking antibody, enhancing the immune system’s ability to detect and destroy cancer cells. Over time, Merck has invested heavily in clinical trials testing Keytruda in earlier disease stages and in combination with other therapies, which has resulted in a growing number of indications and treatment settings. This expanded usage helps sustain volume growth even as competition intensifies in the immuno-oncology field.

Merck’s strategy involves defending Keytruda’s position through robust evidence generation and lifecycle management, including exploring subcutaneous formulations and novel combination regimens. These efforts could extend the product’s relevance and competitive edge, even as the broader market shifts and new agents emerge. For Merck stock, the success of these lifecycle initiatives is closely watched because they influence the timing and magnitude of any eventual decline in Keytruda revenue once biosimilar competition becomes possible.

Research investment and long-term positioning

The scale of Merck’s R&D budget - with around $13.5 billion spent in 2023 - positions the company among the largest research investors in global pharmaceuticals. This level of spending supports a wide portfolio of clinical programs spanning oncology, vaccines, cardiometabolic conditions, and other areas. While heavy R&D investment can pressure near-term EPS, it is a necessary underpinning for future growth, aligning Merck with peers that prioritize innovation over short-term margin maximization. The company aims to convert this research spending into multiple new products that can gradually diversify earnings beyond Keytruda and Gardasil.

Merck’s strategic positioning also includes partnerships and licensing arrangements that leverage external innovation. Collaborations allow Merck to access promising science without bearing the full cost of early-stage development, while the company’s commercial scale and regulatory experience can help bring partnered assets to market efficiently. For Merck stock, these alliances add optionality to the pipeline and can support valuation if they yield successful new therapies.

Product focus: Keytruda in oncology care

In oncology practice, Keytruda has become one of the most widely used immunotherapies worldwide. The drug’s 2023 revenue of about $25.0 billion reflects not only strong demand in the United States but also a growing presence in Europe, Asia, and other regions. Clinical data have demonstrated benefits in survival and disease progression across multiple cancer types, leading to broad guideline recommendations. Hospitals and cancer centers frequently incorporate Keytruda into standard treatment regimens for eligible patients, making it a central component of modern immuno-oncology.

Merck continues to study Keytruda both as monotherapy and in various combination regimens, including pairing it with chemotherapy, targeted therapies, or other immune-modulating agents. The aim is to further improve outcomes and potentially move into earlier lines of therapy, where successful trials can significantly expand the addressable patient population. The product’s performance is therefore both a clinical and financial cornerstone for Merck, directly influencing earnings and shaping perceptions of Merck stock.

Merck stock and recent trading context

Merck stock trades primarily on the New York Stock Exchange under the ticker symbol MRK. At recent typical levels observed over the past year, Merck shares have often been quoted in a price range that positions the company among the larger constituents of the S&P 500 healthcare sector, with market capitalization broadly in the tens of billions of dollars. The share price tends to reflect expectations for continued double-digit growth in Keytruda and Gardasil, weighed against patent timelines and wider macroeconomic conditions.

Over rolling twelve-month periods, Merck’s total return profile has generally combined modest price appreciation with the dividend yield of around mid-single digits, a combination that appeals to investors seeking both income and exposure to healthcare growth trends. As a result, Merck stock is frequently included in diversified equity portfolios and healthcare-focused funds, where it provides a blend of defensiveness and innovation-driven upside.